# A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma

> **NCT04834973** · PHASE1,PHASE2 · TERMINATED · sponsor: **QBiotics Group Limited** · enrollment: 3 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** tigilanol tiglate
- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT04834973
- **Lead sponsor:** QBiotics Group Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-07
- **Primary completion:** 2022-07-12
- **Final completion:** 2022-07-12
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Insufficient Patient Recruitment Rates
- **Last updated:** 2023-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04834973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04834973, "A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04834973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*